DSGN
NASDAQ · Biotechnology
Design Therapeutics Inc
$12.44
+0.51 (+4.27%)
DSGN News7 articles
MeiraGTx Stock Dips 5.5% After Weekly Slide; FDA Designation and Funding in Focus
MeiraGTx shares fell 5.5% Friday to $9.40, ending a 4.3% weekly drop, as the company reported a Q1 net loss of $46.3 million and advanced regulatory filings for key gene therapies.
Oklo Earnings in Focus After NRC Design Approval
Oklo Inc. reports Q1 earnings Tuesday, with analysts expecting a 19-cent loss, following NRC approval of key design criteria for its Aurora reactor.
Oklo Gains NRC Approval for Aurora Design, but Commercial Hurdles Remain
Oklo Inc. received NRC approval for its Aurora powerhouse design, halving the review time. Yet, the company has no built plants or binding power deals, and faces significant hurdles.
Figma Shares Rally 7% Ahead of Q1 Report Amid AI Design Competition
Figma shares jumped 7% to $20.08 ahead of its May 14 earnings report. Analysts remain cautious with a consensus 'Hold' rating, as AI rivals Anthropic and Google challenge the design software leader.
Aterian Surges 89% on $18M Brand Sale and CEO-Designate Investment
Aterian Inc. shares surged 89% after the company agreed to sell its e-commerce brands for $18 million and secured a $7 million investment from David Lazar, who will become CEO.
Synopsys Deepens TSMC Alliance for AI Chip Design Tools
Synopsys announced expanded collaboration with TSMC on advanced chipmaking and packaging for AI, unveiling new design tools for 3nm, 2nm, A16, and A14 nodes. Shares rose to $483.00.
AWS Migrates Defense AI Work from Anthropic Following Pentagon Risk Designation
Amazon Web Services is moving defense-related AI workloads away from Anthropic's Claude model following a Pentagon supply-chain risk designation. The shift comes as Anthropic sues the government over the ban.